Abstract
L-thyroxine (LT4) treatment of hypothyroidism, particularly in patients with thyroid-stimulating hormone (TSH) >10mU/L, results in improved lipid profile, as LT4 stimulates low-density lipoprotein cholesterol (LDL-C) degradation and the conversion of cholesterol in bile acids by inducing LDL-receptor and 7 alpha hydroxylase expression, respectively. Statins decrease total cholesterol (TC) and LDL-C mainly by suppressing 3-hydroxy-3-methylglutaryl coenzyme A activity. Therefore, the addition of statins to LT4 treatment, following the reversal of hypothyroidism, acts synergistically and forms a powerful treatment modality in patients with this condition whose serum lipids have not achieved the target. Statin add-on therapies, such as ezetimibe (EZE) and the recently approved proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, in conjunction with LT4 therapy, produce an even more favorable profile. Ezetimibe blocks the intestinal absorption of cholesterol, while in patients with heterozygous familiar hyperlipidemia, PCSK9 inhibitors suppress PCSK9, thereby promoting LDL-C degradation. The synergy of these drugs results in a far better lipidemic profile than when each drug is administered alone, with LT4 treatment clearly enhancing, in many respects, the efficacy of therapy.
Article PDF
Similar content being viewed by others
References
Duntas LH, Brenta G, 2012 The effect of thyroid disorders on lipid levels and metabolism. Med Clin North Am 96: 269–281.
Steinberg AD, 1968 Myxedema and coronary artery disease—a comparative autopsy study. Ann Intern Med 68: 338–344.
Bastenie PA, Vanhaelst L, Golstein J, Smets P, 1977 Asymptomatic autoimmune thyroiditis and coronary heart-disease. Cross-sectional and prospective studies. Lancet 2: 155–158.
Wadhera RK, Steen DL, Khan I, Giugliano RP, Foody JM, 2016 A review of low-density lipoprotein cholesterol, treatment strategies, and its impact on cardiovascular disease morbidity and mortality. J Clin Lipidol 10: 472–489.
Stamler J, Daviglus ML, Garside DB, Dyer AR, Greenland P, Neaton JD, 2000 Relationship of baseline serum cholesterol levels in 3 large cohorts of younger men to long-term coronary, cardiovascular, and all-cause mortality and to longevity. JAMA 284: 311–318.
Anderson KM, Castelli WP, Levy D, 1987 Cholesterol and mortality. 30 years of follow-up from the Framingham study. JAMA 257: 2176–2180.
Pletcher MJ, Vittinghoff E, Thanataveerat A, Bibbins-Domingo K, Moran AE, 2016 Young adult exposure to cardiovascular risk factors and risk of events later in life: The Framingham Offspring Study. PLoS One 11: e0154288.
März W, Scharnagl H, Gouni-Berthold I, et al, 2016 LDL-Cholesterol: Standards of treatment 2016: A German Perspective. Am J Cardiovasc Drugs 16: 323–336.
Li Z, Hou Z, Yin W, et al, 2016 Effects of statin therapy on progression of mild noncalcified coronary plaque assessed by serial coronary computed tomography angiography: A multicenter prospective study. Am Heart J 180: 29–38.
Gotto AM Jr, Farmer JA, 2006 Drug insight: the role of statins in combination with ezetimibe to lower LDL cholesterol. Nat Clin Pract Cardiovasc Med 3: 664–672.
Blom DJ, Dent R, Castro RC, Toth PP, 2016 PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab. Vasc Health Risk Manag 12: 185–197.
Ray KK, Kastelein JJ, Boekholdt SM, et al, 2014 The ACC/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: the good the bad and the uncertain: a comparison with ESC/EAS guidelines for the management of dyslipidaemias 2011. Eur Heart J 35: 960–968.
Barkas F, Milionis H, Kostapanos MS, Mikhailidis DP, Elisaf M, Liberopoulos E, 2015 How effective are the ESC/EAS and 2013 ACC/AHA guidelines in treating dyslipidemia? Lessons from a lipid clinic. Curr Med Res Opin 31: 221–228.
Gitt AK, Lautsch D, Ferneres J, et al, 2016 Low-density lipoprotein cholesterol in a global cohort of 57,885 statin-treated patients. Atherosclerosis 255: 200–209.
Tagami T, Kimura H, Ohtani S, et al. PHPH study group, 2011 Multi-center study on the prevalence of hypothyroidism in patients with hypercholesterolemia. Endocr J 58: 449–457.
Baron DN, 1956 Hypothyroidism; its aetiology and relation to hypometabolism, hypercholesterolaemia, and increase in body-weight. Lancet 271: 277–281.
Duntas LH, 2002 Thyroid and lipids. Thyroid 12: 287–293.
Shin DJ, Osborne TF, 2003 Thyroid hormone regulation and cholesterol metabolism are connected through sterol regulatory element-binding protein-2 (SREBP-2). J Biol Chem 278: 34114–34118.
Ness GC, Pendleton LC, Li YC, Chiang JY, 1990 Effect of thyroid hormone on hepatic cholesterol 7 alpha hydroxylase, LDL receptor, HMG-CoA reductase, farnesyl pyrophosphate synthetase and apolipoprotein A-I mRNA levels in hypophysectomized rats. Biochem Biophys Res Commun 172: 1150–1156.
Lammel Lindemann JA, Angajala A, Engler DA, Webb P, Ayers SD, 2014 Thyroid hormone induction of human cholesterol 7 alpha-hydroxylase (Cyp7al) in vitro. Mol Cell Endocrinol 388: 32–40.
Song Y, Xu C, Shao S, et al, 2015 Thyroid-stimulating hormone regulates hepatic bile acid homeostasis via SREBP-2/HNF-4alpha/CYP7Al axis. J Hepatol 62: 1171–1179.
Tan KC, Shiu SW, Kung AW, 1998 Effect of thyroid dysfunction on high-density lipoprotein subfraction metabolism: roles of hepatic lipase and cholesteryl ester transfer protein. J Clin Endocrinol Metab 83: 2921–2924.
Valdemarsson S, Nilsson-Ehle P, 1987 Hepatic lipase and the clearing reaction: studies in euthyroid and hypothyroid subjects. Horm Metab Res 19: 28–30.
Zambon A, Deeb SS, Bensadoun A, Foster KE, Brunzell JD, 2000 In vivo evidence of a role for hepatic lipase in human apoB-containing lipoprotein metabolism, independent of its lipolytic activity. J Lipid Res 41: 2094–2099.
Ito M, Takamatsu J, Matsuo T, et al, 2003 Serum concentrations of remnant-like particles in hypothyroid patients before and after thyroxine replacement. Clin Endocrinol (Oxf) 58: 621–626.
Varbo A, Benn M, Nordestgaard BG, 2014 Remnant cholesterol as a cause of ischemic heart disease: evidence, definition, measurement, atherogenicity, high risk patients, and present and future treatment. Pharmacol Ther 141: 358–367.
Kuusi T, Taskinen MR, Nikkila EA, 1988 Lipoproteins, lipolytic enzymes, and hormonal status in hypothyroid women at different levels of substitution. J Clin Endocrinol Metab 66: 51–56.
Gjedde S, Gormsen LC, Rungby J, et al, 2010 Decreased lipid intermediate levels and lipid oxidation rates despite normal lipolysis in patients with hypothyroidism. Thyroid 20: 843–849.
O’Brien T, Dinneen SF, O’Brien PC, Palumbo PJ, 1993 Hyperlipidemia in patients with primary and secondary hypothyroidism. Mayo Clin Proc 68: 860–866.
Brenta G, Vaisman M, Sgarbi JA, et al, 2013 Clinical practice guidelines for the management of hypothyroidism. Arq Bras Endocrinol Metabol 57: 265–291.
National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III), 2002 Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106: 3143–3421.
Garber JR, Cobin RH, Gharib H, et al, 2012 2012 Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Endocr Pract 18: 988–1028.
Song Y, Zhao M, Zhang H, et al, 2016 Thyroid stimulating hormone levels are inversely associated with serum total bile acid levels: a cross-sectional study. Endocr Pract 22: 420–426.
Liu XL, He S, Zhang SF, et al, 2014 Alteration of lipid profile in subclinical hypothyroidism: a meta-analysis. Med Sci Monit 20: 1432–1441.
Danese MD, Ladenson PW, Meinert CL, Powe NR, 2000 Clinical review 115: effect of thyroxine therapy on serum lipoproteins in patients with mild thyroid failure: a quantitative review of the literature. J Clin Endocrinol Metab 85: 2993–3001.
Cappola AR, Fried LP, Arnold AM, et al, 2006 Thyroid status, cardiovascular risk, and mortality in older adults. JAMA 295: 1033–1041.
Lioudaki E, Mavroeidi NG, Mikhailidis DP, Ganotakis ES, 2013 Subclinical hypothyroidism and vascular risk: an update. Hormones (Athens) 12: 495–506.
Rugge JB, Bougatsos C, Chou R, 2015 Screening and treatment of thyroid dysfunction: an evidence review for the U.S. Preventive Services Task Force. Ann Intern Med 162: 35–45.
Linton MF, Yancey PG, Davies SS, et al In: De Groot LJ, Beck-Peccoz P, Chrousos G, et al (eds), 2000–2015 The Role of lipids and lipoproteins in atherosclerosis. SourceEndotext [Internet]. South Dartmouth (MA): MDText.com, Inc.
Duntas LH, Mantzou E, Koutras DA, 2002 Circulating levels of oxidized low-density lipoprotein in overt and mild hypothyroidism. Thyroid 12: 1003–1007.
Arikan S, Bahceci M, Tuzcu A, Celik F, Gokalp D, 2012 Postprandial hyperlipidemia in overt and subclinical hypothyroidism. Eur J Intern Med 23: e141–145.
Boren J, Williams KJ, 2016 The central role of arterial retention of cholesterol-rich apolipoprotein-B-containing lipoproteins in the pathogenesis of atherosclerosis: a triumph of simplicity. Curr Opin Lipidol 27: 473–483.
Brenta G, Berg G, Arias P, et al, 2007 Lipoprotein alterations, hepatic lipase activity, and insulin sensitivity in subclinical hypothyroidism: response to L-T(4) treatment. Thyroid 17: 453–460.
Ito M, Takamatsu J, Sasaki I, et al, 2004 Disturbed metabolism of remnant lipoproteins in patients with subclinical hypothyroidism. Am J Med 117: 696–699.
Brenta G, Berg G, Zago V, et al, 2008 Proatherogenic mechanisms in subclinical hypothyroidism: hepatic lipase activity in relation to the VLDL remnant IDL. Thyroid 18: 1233–1236.
Brenta G, Berg G, Miksztowicz V, et al, 2016 Atherogenic lipoproteins in subclinical hypothyroidism and their relationship with hepatic lipase activity: response to replacement treatment with levothyroxine. Thyroid 26: 365–372.
Lopez D, Abisambra Socarrás JF, Bedi M, Ness GC, 2007 Activation of the hepatic LDL receptor promoter by thyroid hormone. Biochim Biophys Acta 1771: 1216–1225.
Lin JZ, Martagón A J, Hsueh WA, et al, 2012 Thyroid hormone receptor agonists reduce serum cholesterol independent of the LDL receptor. Endocrinology 153: 6136–6144.
Irving SA, Vadiveloo T, Leese GP, 2015 Drugs that interact with levothyroxine: an observational study from the Thyroid Epidemiology, Audit and Research Study (TEARS). Clin Endocrinol (Oxf) 82: 136–141.
Abbasinazari M, Nakhjavani M, Gogani S, 2011 The effects of simvastatin on the serum concentrations of thyroid stimulating hormone and free thyroxine in hypothyroid patients treated with levothyroxine. Iran J Med Sci 36: 80–83.
Rennert G, Rennert HS, Pinchev M, Gruber SB, 2010 A case-control study of levothyroxine and the risk of colorectal cancer. J Natl Cancer Inst 102: 568–572.
Gullu S, Emral R, Bastemir M, Parkes AB, Lazarus JH, 2005 In vivo and in vitro effects of statins on lymphocytes in patients with Hashimoto’s thyroiditis. Eur J Endocrinol 153: 41–48.
Krysiak R, Szkróbka W, Okopień B, 2016 The Effect of Ezetimibe/Statin combination and high-dose statin therapy on thyroid autoimmunity in women with Hashimoto’s thyroiditis and cardiovascular disease: A pilot Study. Exp Clin Endocrinol Diabetes 124: 577–581.
Khalili H, 2016 Statins for Inflammatory Bowel Disease: Expanding the Scope of Prevention. Am J Gastroenterol 111: 1424–1426.
Cappelli C, Castellano M, Pirola I, et al, 2008 Reduced thyroid volume and nodularity in dyslipidaemic patients on statin treatment. Clin Endocrinol (Oxf) 68: 16–21.
Tokinaga K, Oeda T, Suzuki Y, Matsushima Y, 2006 HMG-CoA reductase inhibitors (statins) might cause high elevations of creatine Phosphokinase (CK) in patients with unnoticed hypothyroidism. Endocr J 53: 401–405.
Lando HM, Burman KD, 2008 Two cases of statin-induced myopathy caused by induced hypothyroidism. Endocr Pract 4: 726–731.
Banach M, Rizzo M, Toth PP, et al, 2015 Statin intolerance — an attempt at a unified definition. Position paper from an International Lipid Expert Panel. Arch Med Sci 11: 1–23.
Moosmann B, Behl C, 2004 Selenoproteins, cholesterol-lowering drugs, and the consequences: revisiting of the mevalonate pathway. Trends Cardiovasc Med 14: 273–281.
Joy TR, 2012 Novel therapeutic agents for lowering low density lipoprotein cholesterol. Pharmacol Ther 135: 31–43.
Davis HR Jr, Altmann SW, 2009 Niemann-Pick C1 Like 1 (NPC1L1) an intestinal sterol transporter. Biochim Biophys Acta 1791: 679–683.
Cannon CP, Blazing MA, Giugliano RP, et al, 2015 Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 372: 2387–2397.
Rosen JB, Ballantyne CM, Hsueh WA, et al, 2015 Influence of metabolic syndrome factors and insulin resistance on the efficacy of ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome and atherosclerotic coronary heart disease risk. Lipids Health Dis 14: 103.
Ananthakrishnan S, Braverman LE, Levin RM, Magnani B, Pearce EN, 2008 The effect of famotidine, esomeprazole, and ezetimibe on levothyroxine absorption. Thyroid 18: 493–498.
Seedorf U, Engel T, Lueken A, et al, 2004 Cholesterol absorption inhibitor Ezetimibe blocks uptake of oxidized LDL in human macrophages. Biochem Biophys Res Commun 320: 1337–1341.
Krysiak R, Zmuda W, Okopien B, 2012 The effect of ezetimibe, administered alone or in combination with simvastatin, on lymphocyte cytokine release in patients with elevated cholesterol levels. J Intern Med 271: 32–42.
Moutzouri E, Tellis CC, Rousouli K, et al, 2012 Effect of simvastatin or its combination with ezetimibe on Toll-like receptor expression and lipopolysaccharide — induced cytokine production in monocytes of hypercholesterolemic patients. Atherosclerosis 225: 381–387.
Bonde Y, Plösch T, Kuipers F, Angelin B, Rudling M, 2012 Stimulation of murine biliary cholesterol secretion by thyroid hormone is dependent on a functional ABCG5/G8 complex. Hepatology 56: 1828–1837.
Gälman C, Bonde Y, Matasconi M, Angelin B, Rudling M, 2008 Dramatically increased intestinal absorption of cholesterol following hypophysectomy is normalized by thyroid hormone. Gastroenterology 134: 1127–1136.
Yamanashi Y, Takada T, Yoshikado T, Shoda J, Suzuki H, 2011 NPC2 regulates biliary cholesterol secretion via stimulation of ABCG5/G8-mediated cholesterol transport. Gastroenterology 140: 1664–1674.
Seidah NG, Awan Z, Chrétien M, Mbikay M, 2014 PCSK9: a key modulator of cardiovascular health. Circ Res. 114: 1022–1036.
Achimastos A, Alexandrides T, Alexopoulos D, et al, 2016 Expert consensus on the rational clinical use of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. Hormones (Athens) 15: 8–14.
Saxon DR, Eckel RH, 2016 Statin Intolerance: A literature review and management strategies. Prog Cardiovasc Dis 59: 153–164.
Sullivan D, Olsson AG, Scott R, et al, 2012 Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial. JAMA 308: 2497–2506.
Myant NB, 1983 The metabolic basis of familial hypercholesterolemia. Klin Wochenschr 61: 383–401.
Thompson GR, Soutar AK, Spengel FA, et al, 1981 Defects of receptor-mediated low density lipoprotein catabolism in homozygous familial hypercholesterolemia and hypothyroidism in vivo. Proc Natl Acad Sci USA 78: 2591–2595.
Besseling J, Hovingh GK, Huijgen R, Kastelein JJ, Hutten BA, 2016 Statins in familial hypercholesterolemia: Consequences for coronary artery disease and all-cause mortality. Am Coll Cardiol 68: 252–260.
Awan Z, Seidah NG, MacFadyen JG, et al, 2012 Rosuvastatin, proprotein convertase subtilisin/kexin type 9 concentrations, and LDL cholesterol response: the JUPITER trial. Clin Chem 58: 183–189.
Catapano AL, Lautsch D, Tokgözoglu L, et al, 2016 Prevalence of potential familial hypercholesteremia (FH) in 54,811 statin-treated patients in clinical practice. Atherosclerosis 252: 1–8.
Dong B, Singh AB, Fung C, Kan K, Liu J, 2014 CETP inhibitors downregulate hepatic LDL receptor and PCSK9 expression in vitro and in vivo through a SREBP2 dependent mechanism. Atherosclerosis 235: 449–462.
Kwakernaak AJ, Lambert G, Muller Kobold AC, Dullaart RP, 2013 Adiposity blunts the positive relationship of thyrotropin with proprotein convertase subtilisin-kexin type 9 levels in euthyroid subjects. Thyroid 23: 166–172.
Wang F, Tan Y, Wang C, et al, 2012 Thyroid-stimulating hormone levels within the reference range are associated with serum lipid profiles independent of thyroid hormones. J Clin Endocrinol Metab. 97: 2724–2731.
Ferri N, Ruscica M, 2016 Proprotein convertase subtilisin/kexin type 9 (PCSK9) and metabolic syndrome: insights on insulin resistance, inflammation, and atherogenic dyslipidemia. Endocrine 54: 588–601.
Bonde Y, Breuer O, Lutjohann D, et al, 2014 Thyroid hormone reduces PCSK9 and stimulates bile acid synthesis in humans. J Lipid Res 55: 2408–2415.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Duntas, L.H., Brenta, G. Thyroid hormones: a potential ally to LDL-cholesterol-lowering agents. Hormones 15, 500–510 (2016). https://doi.org/10.14310/horm.2002.1707
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.14310/horm.2002.1707